Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity

Journal of Immunology

Volumn 163, Issue 1, 1999, Pages 507-513

  Clay, Timothy M ^a   Custer, Mary C ^a   Sachs, Jessica ^a   Hwu, Patrick ^a   Rosenberg, Steven A ^a   Nishimura, Michael I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ARTICLE; CANCER IMMUNOTHERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; LYMPHOCYTE CLONE; MELANOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN TARGETING;

ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLONE CELLS; CYTOTOXICITY TESTS, IMMUNOLOGIC; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOPHENOTYPING; MELANOMA; MOLONEY MURINE LEUKEMIA VIRUS; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTE SUBSETS; TUMOR CELLS, CULTURED;

EID: 0033168142     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Robbins, P. F., and Y. Kawakami. 1996 Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 8:628.
2. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
3. Mandruzzato, S., F. Brasseur, G. Andry, T. Boon, and P. van der Bruggen. 1997. A CASP-8 mutation recognized by cytotoxic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186:785.
4. Brandle, D., F. Brasseur, P. Weynants, T. Boon, and B. Van den Eynde. 1996. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med. 183:2501.
5. Gaugler, B., N. Brouwenstijn, V. Vantomme, J. P. Szikora, C. W. Van der Spek, J. J. Patard, T. Boon, P. Schrier, and B. J. Van den Eynde. 1996. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 44:323.
6. Kast, W. M., R. Offringa, P. J. Peters, A. C. Voordouw, R. H. Meloen, A. J. van der Eb, and C. J. Melief. 1989. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 59:603.
7. Rodolfo, M., C. Bassi, C. Salvi, and G. Parmiani. 1991. Therapeutic use of a long-term T cell line recognizing a common tumor-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumors. Cancer Immunol. Immunother. 34:53.
8. Feltkamp, M. C., G. R. Vreugdenhil, M. P. M. Vierboom, E. Ras, S. H. van der Burg, J. ter Schegget, C. J. M. Melief, and W. M. Kast. 1995. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol. 25:2638.
9. Burger, U. L., M. P. Chang, M. Nagoshi, P. S. Goedegebuure, and T. J. Eberlain. 1996. Improved in vivo efficiency of tumor-infiltrating lymphocytes after restimulation with irradiated tumor cells in vitro. Ann. Surg. Oncol. 3:580.
10. Shilyansky, J., J. C. Yang, M. C. Custer, P. Spiess, A. Mixon, D. J. Cole, J. J. Mule, S. A. Rosenberg, and M. I. Nishimura. 1997. Identification of a T-cell receptor from a therapeutic murine T-cell clone. J. Immunother. 20:247.
11. Rosenberg, S., J. Yannelli, J. Yang, S. Topalian, D. Schwartzentruber, J. Weber, D. Parkinson, C. Seipp, J. Einhorn, and D. White. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86:1159.
12. Crowley, N. J., C. L. Slingluff, Jr., T. L. Darrow, and H. F. Seigler. 1990. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. Cancer Res. 50:492.
13. Stevens, E. J., L. Jacknin, P. F. Robbins, Y. Kawakami, M. El Gamil, S. A. Rosenberg, and J. R. Yannelli. 1995. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines: fine specificity and MART-1 melanoma antigen recognition. J. Immunol. 154:762.
14. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515.
15. Marincola, F. M., Y. M Hijazi, P. Fetsch, M. L. Salgaller, L. Rivoltini, J. Cormier, T. B. Simonis, P. H. Duray, M. Herlyn, Y. Kawakami, and S. A. Rosenberg. 1996. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in situ lesions. J. Immunother. 19:192.
16. Cole, D. J., D. P. Weil, J. Shilyansky, M. Custer, Y. Kawakami, S. A. Rosenberg, and M. I. Nishimura. 1995. Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res. 55:748.
17. Rosenberg, S. A., O. Aebersold, K. Cornetta, A. Kasid, R. A. Morgan, R. Moen, E. M. Karson, M. T. Lotze, J. C. Yang, S. L. Topalian, M. J. Merino, K. Culver, A. D. Miller, R. M. Blaese, and W. F. Anderson. 1990. Gene transfer into humans: immunotherapy of patients with advanced melanoma using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323:570.
18. Lam, J. S., M. E. Reeves, R. Cowherd, S. A. Rosenberg, and P. Hwu. 1996. Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope. Hum. Gene Ther. 7:1415.
19. Treisman, J., P. Hwu, S. Minamoto, G. E. Shafer, R. Cowherd, R. A. Morgan, and S. A. Rosenberg. 1995. Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood 85:139.
20. Miller, A. D., J. V. Garcia, N. von Suhr, C. M. Lynch, C. Wilson, and M. V. Eiden. 1991. Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol. 65:2220.
21. Bunnell, B. A., L. M. Muul, R. E. Donahue, R. M. Blaese, and R. A. Morgan. 1995. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. Proc. Natl. Acad. Sci. USA 92:7739.
22. Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038.
23. Topalian, S. L., D. Soloman, and S. A. Rosenberg. 1989. Tumor specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142:3714.
24. Rosenberg, S. A., B. Packard, P. Aebersold, D. Solomon, S. Topalian, S. Toy, P. Simon, M. Lotze, J. Yang, C. Seipp, C. Simpson, C. Carter, S. Bock, D. Schwartzentruber, J. Wei, and D. White. 1988. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: preliminary report. N. Engl. J. Med. 319:1676.
25. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanomareactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:2539.
26. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X-Q. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 associated with in vivo tumor regression. J. Immunol. 154:3961.
27. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
28. Mosse, C. A., L. Meadows, C. J. Luckey, D. J. Kittlesen, E. L. Huczko, C. L. Slingluff, Jr., J. Shabanowitz, D. F. Hunt, and V. H. Engelhard. 1998. The class I antigen-processing pathway for the membrane protein tyrosinase involves translation in the endoplasmic reticulum and processing in the cytosol. J. Exp. Med. 187:37.
29. Kawakami, Y., S. A. Rosenberg, and M. T. Lotze. 1988. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J. Exp. Med. 168:2183.
30. Kawasaki, E. S. 1990. Sample preparation from blood, cells and other fluids. In PCR Protocols. M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White, eds. Academic Press, San Diego, CA, pp. 146-152.
31. WHO-IUIS nomenclature sub-committee on TCR designation. 1995. Nomenclature for T-cell receptor (TCR) gene segments of the immune system. Immunogenetics 42:451.
32. Arden, B., S. P. Clark, D. Kabelitz, and T. W. Mak. 1995. Human T-cell receptor variable gene segment families. Immunogenetics 42:455.
33. Fames, J. R. 1989. Molecular biology and function of CD4 and CD8. Adv. Immunol. 44:265.
34. Matsui, K., P. A. Reay, H. Schild, D. S. Fazekas, and M. M. Davis. 1991. Low affinity interaction of peptide-MHC complexes with T cell receptors. Science 254:1788.
35. Doyle, C., and J. L. Strominger. 1987. Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature 330:256.
36. Norment, A. M., R. D. Salter, P. Parham, V. H. Engelhard, and D. R. Littman. 1988. Cell-cell adhesion mediated by CD8 and MHC class II molecules. Nature 336:79.
37. Salter, R. D., R. J. Benjamin, P. K. Wesley, S. E. Buxton, T. P. Garrett, C. Clayberger, A. M. Krensky. A. M. Norment, and D. R. Littman. 1990. A binding site for the T-cell co-receptor CD8 on the α3 domain of HLA-A2. Nature 345:41.
38. Rudd, C. E., J. M. Trevillyan, J. D. Dasgupta, L. L. Wong, and S. F. Schlossman. 1988. The CD4 receptor is complexed in detergent lysates to a protein-tyrosine kinase (pp58) from human T lymphocytes. Proc. Natl. Acad. Sci. USA 85:5190.
39. lck with CD4 in antigen-specific signal transduction in T cells. Cell 64:511.
40. Dembic, Z., W. Haas, R. Zamoyska, J. Parnes, M. Steinmetz, and H. von Boehmer. 1987. Transfection of the CD8 gene enhances T-cell recognition. Nature 326:510.
41. lck. Cell 55:301.
42. + cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A. Cell. Immunol. 139:411.
43. + HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-γ. Cancer Immunol. Immunother. 37:187.
44. - T-cell clone restricted by HLA-A2. Cell. Immunol. 172:52.
45. Player, M. A., K. C. Banacchini, T. B. Simonis, L. Rivoltini, F Arienti, C. Castelli, A. Mazzocchi, F. Belli, G. Parmiani, and F. M. Marincola. 1996. Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols. J. Immunother. Emphasis. Tumor Immunol. 19:357.
46. Marincola, F. M., P. Shamamian, L. Rivoltini, M. Salgaller, J. Cormier, N. P. Restifo, T. B. Simonis, D. Venzon, D. E. White, and D. R. Parkinson. 1996. HLA associations in the antitumor response against malignant melanoma. J. Immunother. 18:242.
47. McKee, M. D., T. M. Clay, S. A. Rosenberg, and M. I. Nishimura. 1999. Quantitation of T-cell receptor frequencies by competitive PCR: generation and evaluation of novel TCR subfamily and clone specific competitors. J. Immunother. 22:93.
48. 111Indium-labelled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Cancer 73:1731.
49. + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer 66:470.
50. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. F. Robbins, F. M. Marincola, M. L. Salgaller, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol. 154: 2257.
51. Marincola, F. M., L. Rivoltini, M. L. Salgaller, M. Player, and S. A Rosenberg. 1996. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J. Immunother. 19:266.